What’s Driving Oncology HTAs in South Korea?

December 10, 2020

Reimbursement in South Korea depends upon a favorable review by Health Insurance Review Agency (HIRA), and some therapies may not be reimbursed because of shortcomings from the perspective of HIRA. To help pharma companies plan clinical trials and economic evidence submission in order to achieve favorable access in South Korea, DRG used the Context Matters Market Access Platform to analyze the clinical and economic rationales behind HIRA’s decisions for 15 oncology indications over the past 5 years. Find out more here.

(Source: Himani Jaiswal, Global Market Access; DRG; 11/3/20)

Share This Story!